肺癌分NSCLC同SCLC
NSCLC有唔少evidence
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653127/
Results showed a significant benefit of chemotherapy (HR, 0.77; 95% CI, 0.71 to 0.83; P ≤ .0001), equivalent to a relative increase in survival of 23% or an absolute improvement in survival of 9% at 12 months, increasing survival from 20% to 29%.
SCLC少人做,得啲細RCT
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001990.pub3/full
Nevertheless, the impact of first‐line chemotherapy on quality of life, older patients, women and patients with poor prognosis is unknown and the benefits of second‐line chemotherapy are also unclear for older people. Globally, the evidence on which these conclusions are based is very scarce and of uncertain or low quality.
新嘅RCT通常唔係比較做chemo vs唔做,而係比較唔同做法
https://tlcr.amegroups.org/article/view/18904/html
當然你可以話效果冇想像中咁好,我都同意醫生要同病人做好expectation management
但至少駁到「cancer病人似俾化療殺死」呢個assertion